Naproxen Sodium Cr (Naproxen Sodium) Patent Expiration, LOE Window & CMS Spending

Naproxen Sodium Cr (Naproxen Sodium) by Bionpharma: FDA Orange Book LOE 2026-03-03, 22 AB generics, $2.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBionpharma
FDA Application & PathwayN021920 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-03-03
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors22
2024 CMS Total Public Spend$2.1M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$969K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel